Improving CAR T cell therapy against malignancies through gene knock-down/out strategies: a systematic review.

ABSTRACT:

Background

CAR T cells still face numerous obstacles in treating hematologic and solid malignancies. Although gene editing technologies have improved CAR T cell therapy, there are currently no systematic reviews to broadly address preclinical and clinical outcomes of gene-edited CAR T cells. Therefore, we aimed to systematically review the preclinical and clinical studies that evaluate the outcomes of knocked-out/knocked-down (KO/KD) CAR T cells.

Methods

This study was submitted to international Prospective Register of Systematic Reviews (PROSPERO) with the ID CRD42022320541 and follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched Five databases (PubMed, EMBASE, Cochrane Library, Web of Science, and Clinicaltria

SUBMITTER: Karimi A 

PROVIDER: S-EPMC12797449 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature